Index

A
Ablatherm®, 183
Ablative treatments, 180
Acute renal insufficiency, 16
Acute urinary retention (AUR), 14, 53
Adenosis, 31
Ageing, 171
Alfuzosin, 64, 70
Alpha-1 antagonists, 34
Alpha-blockers, 59–64, 177–179
5α-Reductase (5AR), 6
5α-Reductase inhibitors, 34, 54–59
Anaesthesia, 173
Androgen hypothesis, 6
Androgen receptors (AR), 5
Anterior fibromuscular stroma (AFMS), 23
Anti-cholinergics, 67–68
Anti-muscarinics, 65–66
Apparent diffusion coefficient (ADC), 31, 32
Aquabeam system, 182
AquaBeam®, 180
PAE, 75, 76, 178
prostatic urethral lift, 183–184
stents, 183
transition zone adenoma in, 87
Benign prostatic enlargement
(BPE), 170
Benzopyrans, 180
5F Berenstein catheter, 77
β3-agonists, 66–68
Bilateral bladder neck incisions, 92, 93
Biopsy strategies, 45–47
Bipolar electrosurgical enucleation, 150
Bipolar enucleation, 117
Bipolar TURP (B-TURP), 122, 149
Bladder neck mucosa/vesico-urethral
anastomosis advancement, 134
Bladder outlet obstruction (BOO), 75, 76, 88,
105, 129
Bladder stones, 17
Bookwalter® retractor, 145

B
Benign prostate hyperplasia (BPH), 5, 30, 41,
75, 76, 129, 177
ablative treatments, 180–183
adverse effects, 178
α-blockers, 60–62
β3-agonists, 67–68
emerging medical treatments, 177
experimental medical treatments, 179–180
5α-reductase inhibitors, 55–57
imaging, 28, 30
laser treatments, 180–181
medical treatments, 178
nanorobotics, 184
optimal potential treatment, 178
Cardio Pulmonary Exercise Testing
(CPET), 172
Catheterization, 138
Central zone (CZ), 4, 5, 23, 28
Clot retention, 13
Combination endoscopic laser ablation
of the prostate (CELAP), 90
Combination of Avodart and Tamsulosin
(CombAT) trial, 58
Co-morbid management
anaesthesia, choice of, 173
medical optimisation, 172–173
patient selection, 171–172
post-operative management, 173–174

C
Capsule elasticity, 27
© Springer International Publishing AG 2018
V. Kasivisvanathan, B. Challacombe (eds.), The Big Prostate,
https://doi.org/10.1007/978-3-319-64704-3

189
Concomitant urological pathology, endoscopic management
  cystolitholapaxy, 170–171
  rigid and flexible ureteroscopy, 167–169
  TURBT, 169–170
  upper urinary tract procedures, 171
Cone-beam CT, 79
CT angiography (CTA), 77
Cystolitholapaxy, 170
Cystoscope, 123

D
Delirium, 173
Difficult catheterisation, 13
Diffusion weighted imaging (DWI), 31, 36
Digital rectal examination (DRE), 44, 121
Digital subtraction angiography (DSA), 77
Digital-rectal examination (DRE), 24
Dihydrotestosterone (DHT), 6, 54, 76
Doppler, 27
Dorsal venous complex (DVC), 132
Doxazosin, 63
Dutasteride, 54, 58

E
Eocalcitol, 179
Enucleation, 92, 97
Estimated blood loss (EBL), 137
European Randomized Study of Screening for Prostate Cancer (ERSPC), 44

F
Fibromuscular hyperplasia, 32
Finasteride, 6, 54, 58
Finasteride monotherapy, 63

G
Gleason grading system, 8, 9
Glycine, 121
GreenLight laser, 181
  advantages, 113
  adverse events and sexual function, 107–109
  comparative studies, 114
  mechanism of action, 106
  operative technique, 106–107
  PVP, 110–113
Growth factors, 7

H
Haematuria, 12, 59
Hemostasis, 147
High-Intensity-Focussed Ultrasound (HiFU), 183
High-performance system (HPS), 106
Holmium laser enucleation of the prostate (HoLEP), 87, 91–94, 97, 98, 117, 118, 180
  advantages and limitations, 88
  and prostate cancer active surveillance, 101
  durability, 100
  equipment, 89–91
  YAG laser, 89–91
  morcellation, 91
  gold standard, 101
  and learning curve, 100–101
  OP vs., 99, 150
  patient selection, 88–89
  vs. PVP, 99, 100
  safety and enucleation efficiency, 100
  technique, 92
  enucleation, 92–94
  morcellation, 97–98
  YAG laser, 89
  Hyperechogenic lesions, 24, 32
  Hypotension, 173

I
IDC, 147
International Prostate Symptom Score (IPSS), 172, 179
Intraprostatic protrusion (IPP), 27
Invasion, 9

J
Jackson-Pratt drain, 135

L
Laparoscopic and robotic surgery, 150
Laparoscopic simple prostatectomy (LSP) technique, 129
Laser incision, 94, 97
Laser resectoscopes, 90
Laser treatments, 180
Lower urinary tract symptoms (LUTS), 7, 20, 109, 113, 117, 129, 172
Lymphatic drainage, 3
Magnetic resonance imaging (MRI)
5-alpha reductase blockade, alpha-1 antagonists and PAE, 34
TRUS and MRI/TRUS-fusion biopsies, 35–36
Male pelvis, 2
Male prostate, 1
Malignant lesions, differentiating benign from, 31–33
Maximum enhancement ratio (MER), 34
Memotherm®, 183
Metastasis, 9
Mirabegron, 66
Monopolar TURP (M-TURP), 118
Morcellation, 91, 97, 98
Multidisciplinary team (MDT), 173
Multiparametric magnetic resonance imaging (mpMRI), 23, 26

Nanorobotics, 184
Neodymium:Yttrium-Aluminum-Garnet (Nd:YAG) laser, 106
Nitric oxide (NO) synthase, 75
NX-1207, 179

Open prostatectomy (OP), 99, 105, 118, 143
vs. bipolar electrosurgical enucleation, 150
vs. bipolar TURP, 149
vs. HOLEP, 150
indications, 144
vs. laparoscopic and robotic surgery, 150
operative techniques, 145
outcomes and complications, 148, 149
post-operative management, 148
pre-operative evaluation, 144
vs. PVP, 150
retropubic prostatectomy, 145–147
suprapubic prostatectomy, 147
vs. unipolar TURP, 149
Open simple prostatectomy (OSP), 129

Peripheral zone (PZ), 4, 5, 7, 24

Pfannsteil incision, 145
Phenoxybenzamine, 63
Phosphodiesterase type 5 inhibitors (PDE5-Is), 69, 76
Photoselective vaporization of the prostate (PVP), 99, 100, 105, 119, 180
GreenLight laser, 110
OP vs., 150
PI-RADS scoring system, 32
Plasma kinetic (PK) system, 122
Polylactic-co-glycolic acid, 183
Potassium-titanyl-phosphate (KTP) laser, 99, 106
Pre-emptive hemostasis, 145
Presumed circle area ratio (PCAR), 27
Proactive care for Older Patients undergoing Surgery (POPS), 172
Prostate arterial supply, 3
benign hyperplasia, imaging, 28–30
Doppler, 27
elective presentations
asymptomatic, 21
incidental imaging, 20
lower urinary tract symptoms, 20
mass effect, 21
PSA, in large gland, 18
emergency presentations
acute renal insufficiency, 16–17
acute urinary retention, 14–16
bladder stones, 17–18
clot retention, 13
difficult catheterisation, 13–14
haematuria, 12–13
urine tract infections, 17
imaging of, 24–26
IPP, 27
lymphatic drainage, 3
neurological innervation, 2
pathology, 7–8
cytology, 8
grading, 8
histology, 8
invasion and metastasis, 9
PCAR and capsule elasticity, 27
physiology, 5
androgen hypothesis, 6–7
growth factors, 7
testosterone, 6
role in, 11
vascular supply, 2
zones of, 4–5
Prostate adenoma, 134, 146
access, 132
dissection, 132
Prostate artery embolization (PAE), 34, 178
surgical treatment
anastomoses, identification, 80
independent PAs, 80
literature, 83
prostates larger than 100 cm³, 80–84
rationale, 75, 76
steep oblique projections, 78
superior vesical artery, 79
technical procedure, 77–78
Prostate cancer, 101
Prostatectomies, 144
Prostate-specific antigen (PSA), 18–20, 41–44, 179
density and transition zone density, 42–43
free PSA, 44
kinetics, 43–44
prostate cancer screening risk stratification tools, 44–45
Prostatic adenoma, 133
Prostatic arteries (PAs), 77
Prostatic urethral lift, 183
PRX302, 179
Puboprostatic ligaments, 2

R
Resectoscope, 94, 123
Resistive index, 27
Retropubic prostatectomy, 145
Rezum system, 181
5F Roberts uterine catheter (RUC), 77
Robot-assisted radical prostatectomy (RARP), 153, 158
functional outcomes, 159–161
erectile function, 158
incontinence, 158
oncological outcomes, 154–157
operative time, intra-operative blood loss and hospital stay length, 154
tips and tricks, 162, 163
transperitoneal approach, 162
Robotic-assisted simple prostatectomy (RASP), 129, 132–134, 139, 140
bladder neck mucosa/vesico-urethral anastomosis advancement, 134–135
catheterization duration, 138–139
closure, 135
complications, 138
EBL and transfusion, 137
functional outcomes, 139
cost comparison, 140
learning curve, 139
hospital of stay, length of, 137
indications, 130
operative time, 136
patient position and port placement, 130–131
perioperative outcomes, 135
prostate adenoma
access, 132
dissection, 132–134
Retzius space and apical dissection, 131–132
surgical technique, 130

S
Somatic innervation, 3
Sonoblate®, 183
Spinal anaesthesia, 173
Squamous metaplasia, 7
Stents, 183
Stimulated Emission of Radiation (laser) technology, 105
Suprapubic catheter i, 16
Suprapubic open prostatectomy (SP), 118
Suprapubic prostatectomy, 147
Surgery, indications for, 70
Surgical map, 181

T
Tamsulosin, 63, 70
Testosterone, 6
Teverelix, 179
Tiemann tip catheter, 15
Tolterodine, 66
Transition zone (TZ), 4, 26
Transperineal template prostate biopsies (TTPB), 46
Transrectal ultrasound (TRUS), 24, 25, 35, 121
Transurethral resection of a bladder tumour (TURBT), 169
Transurethral resection of the prostate (TURP), 105, 117, 169
equipment, 121–123
evaluating prostate size, 121
100 cc prostate, 123
management, 126
outcomes, 119–121
treatment, choice of, 118–121
Trigonization technique, 134
Tubuloalveolar gland, 5

U
Unipolar TURP, 149
Upper urinary tract, 171
Ureteroscopy, 167, 168
Urethral catheter, 147
Urine tract infections, 17

Uroflowmetry, 172
UroLift® device, 183
Urolume Wallstent®, 183

V
Vascular supply, 2
Vesico-urethral anastomosis, 134, 135, 139
Vitamin D3 receptor (VDR) analogue, 179

X
Xcelerated Performance System (XPS), 106